A document, unique to regulatory New Drug Application (NDA) submission for the United States, which evaluates the overall summaries and statistical analyses of the combined safety data from the various clinical studies conducted during drug testing. It is submitted to the Food and Drug Administration (FDA) in section 5.3.5.3 of the CTD.
